Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

In August 2014, the World Health Organization (WHO) declared the outbreak of the Ebola virus disease a public health emergency of international concern1. Shortly after, the Canadian government donated a vial of the replication-competent recombinant vesicular stomatitis virus (rVSV)-vectored Zaire ebolavirus (rVSV-ZEBOV) candidate vaccine to the WHO. This vaccine has been studied in nonhuman primates with some promising results, but it has not previously been studied in humans2-4.

Continue reading